AI-Powered Glioblastoma Research

GBM is the most aggressive primary brain tumor. AI agents research blood-brain barrier penetration strategies, immunotherapy, tumor-treating fields, and novel compounds.

Get a $99 personalized brief on Glioblastoma

14 specialist agents compile a 30–50 page brief from PubMed-indexed research, delivered in 48 hours. Refund + free re-brief if not useful.

Standard of Care

Surgical resection, temozolomide + radiation (Stupp protocol), tumor-treating fields (Optune), bevacizumab.

Prevalence

~13,000 new GBM diagnoses per year in the US.

Five-Year Survival

~6.8% overall. Median survival ~15 months with standard treatment.

Key Mutations

IDH1/2
MGMT promoter methylation
EGFRvIII
PTEN loss
TERT promoter

Key Pathways

egfr-signaling
pi3k-akt-mtor
vegf-angiogenesis

Clinical Trial Focus

CAR-T for GBM, oncolytic virus (DNX-2401), convection-enhanced delivery, neoantigen vaccines.